Business Context and Reporting Period
Company: Maravai LifeSciences Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 2, 2026
Event: Entry into a new material definitive credit agreement and termination of a prior credit agreement.
Key Financial Metrics and Debt Structure
- New Term Loan Facility: $150.0 million.
- New Revolving Credit Facility: $30.0 million.
- Total New Credit Capacity: $180.0 million.
- Maturity Date: June 2, 2032 (for both facilities).
- Interest Rate: Variable based on Term SOFR plus a 5.00% margin (subject to a 0.25% stepdown if net leverage ratio is ≤ 3.00:1.00).
- Commitment Fee: 0.50% per annum on the daily unutilized amount of the Revolving Credit Facility.
- Cash Utilization: Approximately $98.5 million of cash on hand was used alongside the New Term Loan proceeds to prepay the prior debt.
Material Changes Versus Prior Period
The company terminated its Prior Credit Agreement dated October 19, 2020, in full. All outstanding borrowings and accrued interest under the prior agreement were prepaid using the proceeds from the new $150.0 million term loan and approximately $98.5 million in cash on hand. The new agreement extends the maturity of the debt to 2032 and establishes new financial covenants and interest rate structures.
Guidance, Covenants, and Risks
- Financial Covenant: If borrowings under the Revolving Credit Facility (plus letters of credit) exceed 40.0% of total commitments, the consolidated first lien net leverage ratio must not exceed 6.50:1.00.
- Mandatory Prepayments: Following the fiscal year ending December 31, 2027, the company must prepay the New Term Loan with a percentage of annual excess cash flow if the consolidated first lien net leverage ratio exceeds 3.00:1.00.
- Collateral and Guarantees: Borrowings are unconditionally guaranteed by Topco and its material domestic subsidiaries and secured by a lien on substantially all assets of loan parties.
- Restrictive Covenants: The agreement includes customary negative covenants restricting the ability to incur additional indebtedness, pay dividends, dispose of assets, engage in mergers, or make acquisitions without consent.
- Events of Default: Include nonpayment, covenant violations, insolvency, court-ordered judgments, and changes of control.
Investor Verification Checklist
- Verify the exact amount of cash on hand remaining after the $98.5 million prepayment.
- Confirm the current consolidated first lien net leverage ratio to assess proximity to the 3.00:1.00 stepdown threshold and the 6.50:1.00 covenant limit.
- Review the definition of "Consolidated EBITDA" in the new Credit Agreement to understand leverage calculations.
- Monitor future asset sales or debt incurrences that may trigger mandatory prepayments under the new agreement.
- Check for any undrawn letters of credit that would count toward the 40.0% utilization threshold for the financial covenant.